OBT-076 is under clinical development by Oxford BioTherapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how OBT-076’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

OBT-076 overview

OBT-076 is under development for the treatment of solid tumor, her2 negative breast cancer, a type of non-Hodgkin lymphoma (NHL), adenoid cystic carcinoma (ACC) of the head and neck, gastric cancer, endometrial cancer, non-small cell lung (NSCLC) cancer, and ovarian cancer and bladder cancers. It is administered through intravenous route as a solution. It is an antibody-drug conjugate (ADC) composed of fully humanized IgG1 monoclonal antibody conjugated to a potent cytotoxic maytansin toxin through a cleavable linker. ADC acts by targeting a type I transmembrane glycoprotein and a C-type lectin receptor Ly75/ CD205. It is being developed based on Oxford Genome Anatomy Project (OGAP) technology.

It was also pancreatic cancer, triple negative breast cancer and diffuse large B-cell lymphoma (DLBCL).

Oxford BioTherapeutics overview

Oxford BioTherapeutics (OBT) is a clinical-stage oncology company that develops immuno-oncology (IO) and antibody-drug conjugate (ADC) drugs to treat cancers. The company’s pipeline product include OBT076, which treats solid tumors, including gastric, bladder, ovarian and lung cancer. Its products are designed to address unmet patient needs in cancer therapeutics, including bispecific, chimeric antigen receptor T Cell (CAR-T), antibody-drug conjugate (ADC) and antibody-dependent cell-mediated cytotoxicity (ADCC) therapeutics. Its OGAP discovery platform is a cancer membrane proteomic database and IO discovery platform that provides insights into the cancer-immune cell synapse. Oxford BioTherapeutics is headquartered in Abingdon, the UK.

For a complete picture of OBT-076’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.